Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Metabolic Syndrome
2007-003131-23Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of olmesartan in cardiometabolic risk (CMR) and hypertension (HTN) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Apr 2008; status: completed.
02
Drugs
olmesartan
03
Conditions
cardiometabolic risk (CMR)hypertension (HTN)
Beyond the preview
Go deeper on 2007-003131-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003131-23.